merck & co. inc.
(MRK:New York Consolidated)
Transactions by MERCK & CO. INC. (MRK) in the last 6 months
Merck & Co. Inc. (NYSE:MRK) agreed to acquire 15% stake in NGM Biopharmaceuticals, Inc. for approximately $110 million on February 23, 2015. Concurrently, Merck & Co. Inc. has entered into a five-year collaboration agreement with NGM Biopharmaceuticals Inc. to research and develop drugs that treat diabetes and obesity. Merck will commit up to $250 million to fund all of NGM’s efforts under the initial five-year term of the collaboration, with the potential for additional ...
Merial Limited agreed to acquire the Merck manufacturing facility in Barceloneta, Puerto Rico from Merck & Co. Inc. (NYSE:MRK) on December 4, 2014. The proposed transaction requires approval from the United States Federal Trade Commission. If approved, the acquisition will allow Merial to expand its global manufacturing operations and make use of the site's expertise in chewables manufacturing technology. As part of the agreement, Merial will retain the approximately ...
Merck & Co. Inc. (NYSE:MRK) acquired OncoEthix SA from Index Ventures, Edmond de Rothschild Investment Partners, S.A.S., Endeavour II of Endeavour Vision SA, SV Life Sciences Advisers, LLC, and others for approximately $380 million on December 18, 2014. Under the terms of transaction, Merck shall make an upfront payment of up to $110 million to OncoEthix. Additional milestone payments of up to $265 million are contingent upon certain clinical and regulatory events being ...
Edmond de Rothschild Investment Partners, S.A.S.
Endeavour Vision SA
SV Life Sciences Advisers, LLC
Merck & Co. Inc. entered into a definitive agreement to acquire Cubist Pharmaceuticals Inc. (NasdaqGS:CBST) from Bellevue Asset Management AG, Deutsche Asset & Wealth Management Investment GmbH, Federated Equity Management Company of Pennsylvania, HBM Partners Ltd.,Tekla Healthcare Investors and Tekla Life Sciences Investors, funds of Tekla Capital Management LLC, and others for $7.8 billion in cash on December 8, 2014. Merck will acquire the shares of Cubist for $102 ...
Deutsche Asset & Wealth Management Investment GmbH
Federated Equity Management Company of Pennsylvania
HBM Partners Ltd.
Tekla Capital Management LLC
Tekla Healthcare Investors
Tekla Life Sciences Investors
Morgan Stanley & Co. LLC
Ropes & Gray LLP
|Gilead Sciences Inc||$103.83 USD||+0.30|
|GlaxoSmithKline PLC||1,554 GBp||+12.50|
|Pfizer Inc||$34.77 USD||+0.45|
|Roche Holding AG||SFr.261.00 CHF||+2.20|
|View Industry Companies|